Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950910 · ClinicalTrials.gov registry record
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 766
- Enrollment target
NCT01950910 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 766 participants.
The verdict
NCT01950910 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 766 participants
- Enrollment target
Study Summary
Biomarkers are essential for the identification of disease states. There are no early diagnostic or prognostic markers for ALS. The purpose of this study is to identify a panel of biomarkers from blood or spinal fluid of ALS patients and to collect data to better understand disease progression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 766 participants |
| Start Date | 2004-03-29 |
| Est. Completion | 2020-10-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950910
The ClinicalTrials.gov registry entry for NCT01950910 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 766 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01950910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950910 about?
NCT01950910 is a clinical study titled "Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)". Biomarkers are essential for the identification of disease states. There are no early diagnostic or prognostic markers for ALS. The purpose of this study is to identify a panel of biomarkers from blood or spinal fluid of ALS patients and to collect data to better understand disease progression.
What is the current status of trial NCT01950910?
This trial is currently terminated. The enrollment target is 766 participants. The study started on 2004-03-29. Estimated completion is 2020-10-29.
Who is sponsoring clinical trial NCT01950910?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.